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Abstract
Background: Infection with human herpesvirus 8 (HHV-8) is the necessary causal agent in the
development of Kaposi's sarcoma (KS). Infection with HIV-1, male gender and older age all increase
risk for KS. However, the geographic distribution of HHV-8 and KS both prior to the HIV/AIDS
epidemic and with HIV/AIDS suggest the presence of an additional co-factor in the development of
KS.
Methods: Between January 1994 and October 1997, we interviewed 2576 black in-patients with
cancer in Johannesburg and Soweto, South Africa. Blood was tested for antibodies against HIV-1
and HHV-8 and the study was restricted to 2191 HIV-1 negative patients. Antibodies against the
latent nuclear antigen of HHV-8 encoded by orf73 were detected with an indirect
immunofluorescence assay. We examined the relationship between high anti-HHV-8 antibody
titers (≥1:51,200) and sociodemographic and behavioral factors using unconditional logistic
regression models. Variables that were significant at p = 0.10 were included in multivariate analysis.
Results: Of the 2191 HIV-1 negative patients who did not have Kaposi's sarcoma, 854 (39.0%)
were positive for antibodies against HHV-8 according to the immunofluorescent assay. Among
those seropositive for HHV-8, 530 (62.1%) had low titers (1:200), 227 (26.6%) had medium titers
(1:51,200) and 97 (11.4%) had highest titers (1:204,800). Among the 2191 HIV-1 negative patients,
the prevalence of high anti-HHV-8 antibody titers (≥1:51,200) was independently associated with
increasing age (ptrend = 0.04), having a marital status of separated or divorced (p = 0.003), using
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wood, coal or charcoal as fuel for cooking 20 years ago instead of electricity (p = 0.02) and
consuming traditional maize beer more than one time a week (p = 0.02; p-trend for increasing
consumption = 0.05) although this may be due to chance given the large number of predictors
considered in this analysis.
Conclusions: Among HIV-negative subjects, patients with high anti-HHV-8 antibody titers are
characterized by older age. Other associations that may be factors in the development of high anti-
HHV-8 titers include exposure to poverty or a low socioeconomic status environment and
consumption of traditional maize beer. The relationship between these variables and high anti-
HHV-8 titers requires further, prospective study.
Background
Human herpesvirus 8 (HHV-8, also known as Kaposi's
sarcoma-associated herpesvirus) is understood to be the
necessary, causal agent in the development of Kaposi's
Sarcoma (KS) [1–3]. HHV-8 has been detected in the
lesions of nearly all patients with Kaposi's sarcoma [4,5]
and it predicts the development of Kaposi's sarcoma when
found in the blood [3,6].
Not all individuals infected with HHV-8 develop KS sug-
gesting the presence of a co-factor in the development of
the malignancy [7,8]. HIV infection, other immunosup-
pression, male gender and older age all increase risk
[9,10]. To explain the geographical variation in KS inci-
dence world-wide, researchers have proposed additional
co-factors. In particular, researchers have suggested that
infection with HHV-8 later in life, high socioeconomic
status and/or exposure to substances in the water or soil
may be potential co-factors increasing risk for KS in adult-
hood [11–13]. High anti-HHV-8 antibody titers have
been correlated with high HHV-8 viral load and increased
risk for development of KS [14–16], but risk factors other
than age and length of infection for elevated titers have
not been determined [17,18]. The aim of our study was to
identify risk factors for high titers to HHV-8 (≥1:51,200)
as a means to better understand risk factors for Kaposi's
sarcoma among HIV-seronegative, black adults in South
Africa. Using a database of information on over 2000 HIV-
1 negative black, South African hospitalized cancer
patients, we conducted a case control study of risk factors
for high titers to HHV-8 (≥1:51,200) using patients with
high titers as cases and HHV-8 infected patients with low
titers as controls (median titer 1:200).
Methods
Study participants
The participants included in our analyses were part of a
large epidemiologic study conducted by researchers from
the South African National Cancer Registry and the
Department of Medicine of the University of the Witwa-
tersrand, in collaboration with investigators in the United
Kingdom as described elsewhere [14]. The study was con-
ducted between January 1994 and October 1997 at three
Johannesburg hospitals (Chris Hani-Baragwanath, Hill-
brow and Johannesburg). Trained nurses interviewed
2576 black inpatients with cancer using a questionnaire in
the language of the patient (most commonly Zulu or
Sotho).
Serologic Tests for HHV-8 and HIV-1
The serum samples were shipped by air on dry ice to the
Institute of Cancer Research in London for HHV-8 testing.
Details of the testing procedure are described elsewhere
[14]. Briefly, a B-cell lymphoma (primary effusion lym-
phoma) cell line, BCP-1, infected with HHV-8 but not
Epstein Barr virus (EBV) was used for an indirect immun-
ofluorescence assay to detect IgG antibodies against HHV-
8 antigen. All assays were examined by a single observer
[2,19]. Slides were screened by ultra-violet microscopy for
the latent nuclear antigen of HHV-8 encoded by orf73
[2,20–24]. Serum samples that were positive for antibod-
ies against HHV-8 by the immunofluorescence assay were
scored as low (median titers were 1:200), medium
(1:51,200) or high (1:204,800) according to the intensity
of the fluorescent signal. These scores correlated well with
intensity of fluorescence as measured by fluorescence-acti-
vated cell sorter (FACS) analysis described in detail in
Sitas et al. 1999.
Statistical Analysis
Within this group of 2576 black inpatients interviewed
between 1994–1997, serum samples from 2329 (90 per-
cent) were tested for antibodies to HHV-8. We restricted
analyses to those patients who were HIV-1 negative and
without KS. A total number of 2191 HIV-1 negative
patients without KS who were tested for HHV-8 form the
basis for the analysis presented in this paper. We decided
to restrict the study to HIV-1 negative patients so as to
remove the confounding between level of immunosup-
pression and high HHV-8 titers or risk of Kaposi's sarcoma
[25]. Since the factors influencing high titers to HHV-8 are
not known, we initially examined the relation between
high antibody titers to HHV-8 (≥1:51,200) and all ques-
tions from our questionnaire including age, sex, educa-
tion, place of birth, place of residence, parity, number of
lifetime sexual partners, history of contraceptive use forBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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women, frequency and type of alcohol consumption, use
and frequency of tobacco and other lifestyle variables
such as fuel use for cooking and heating and building
materials used in house construction. Odds ratios were
calculated by unconditional logistic regression adjusting
for age group (<35, 35 to 44, 45 to 54, 55 to 64, or ≥ 65)
Table 3: Some factors characterizing wealth in relation to high anti-HHV-8 antibody titers*
Characteristic high titer/total pos (%)¥ aOR * 95%CI
Walls of home (building materials used)
Brick§ 268/727 (36.9) 1.0
Other 56/127 (44.1) 1.49 (1.01–2.21)
Test of Homogeneity¶ χ2 = 4.04, p = 0.04
Location for cooking food now
Inside home§ 308/808 (38.1) 1.0
Outside home 16/45 (35.6) 0.92 (0.49–1.73)
Test of Homogeneity¶ χ2 = 0.06, p = 0.80
Type of fuel used for cooking food now
Electricity § 229/597 (38.4) 1.0
Other 95/256 (37.1) 0.99 (0.73–1.34)
Test of Homogeneity¶ χ2 = 0.01, p = 0.93
Type of fuel used for heating now
Electricity§ 228/595 (38.3) 1.0
Other 96/258 (37.2) 1.00 (0.73–1.35)
Test of Homogeneity¶ χ2 = 0.00, p = 0.98
Location for cooking food 20 years ago
Inside§ 282/749 (37.7) 1.0
Outside 41/108 (39.8) 1.10 (0.72–1.69)
Test of Homogeneity¶ χ2 = 0.20, p = 0.65
Type of fuel used for cooking food 20 years ago
Other§ 306/771 (39.7) 1.0
Electricity 17/81 (21.0) 0.44 (0.25–0.78)
Test of Homogeneity¶ χ2 = 8.08, p = 0.005
Type of fuel used for heating 20 years ago
Other§ 307/773 (39.7) 1.0
Electricity 16/79 (20.3) 0.43 (0.25–0.73)
Test of Homogeneity¶ χ2 = 8.5, p = 0.004
Eyes watering in house from smoke
No§ 142/432 (32.9) 1.0
Yes/ 160/365 (43.8) 1.56 (1.16–2.08)
(More than 5 Years)
Test of Homogeneity¶ χ2 = 8.82, p = 0.003
Working Now
No§ 261/673 (38.7) 1.0
Yes 54/167 (32.3) 0.85 (0.58–1.26)
Test of Homogeneity¶ χ2 = 0.72, p = 0.39
On pension/disability
No§ 153/449 (34.1) 1.0
Yes 163/392 (41.6) 1.01 (0.67–1.52)
Test of Homogeneity¶ χ2 = 0.00, p = 0.97
Occupational status
White-collar§ 37/89 (41.6) 1.0
Non-active 31/99 (31.3) 0.71 (0.38–1.33)
Farming 14/41 (34.2) 0.63 (0.29–1.38)
Industry 72/181 (39.8) 0.85 (0.50–1.44)
Domestic 130/331 (39.3) 0.85 (0.52–1.41)
Unspecified 15/32 (46.9) 1.53 (0.65–3.59)
Test of Homogeneity¶ χ2 (5df) = 4.49, p = 0.48
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients 
served as the reference group. ¶ All values were calculated with the χ2 test with 1 df unless noted otherwise.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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and sex as indicated using STATA [26]. All p-values are 2-
sided. Numbers of cases and controls in the tables do not
always add up to the total because of missing values.
Factors that were significant in bivariate analyses at p=
0.10 were included in a multivariate logistic regression
analysis, to identify which factors, if any, were independ-
ently associated with high HHV-8 titers. Goodness of fit
was assessed by the Hosmer-Lemeshow test [27]. The var-
iable "use of fuel for warming 20 years ago" was not con-
sidered in the multivariate model because it was collinear
with the variable "use of fuel for cooking 20 years ago."
The variable "frequency of sorghum beer consumption"
was also not considered in the multivariate model
because it was collinear with the variable "frequency of
traditional maize beer consumption." We examined the
confounding effect of other variables. In general, con-
founding was defined when inclusion of a variable in the
multivariate model resulted in a change of more than 15
percent in odds ratios of factors already present in the
model. Variables that had a considerable number of
"missings" were modeled in our analysis with a separate
"missing values" category.
Table 1: Sociodemographic Characteristics of Participants in relation to HHV-8 seropositivity and anti-HHV-8 titer level.
Total No. HHV-8 neg 
(%)
No. HHV-8 pos 
(%)
No. low titer (%) No. med. titer (%) No. high titer (%)
TOTAL 2191 1337 (61.0) 854 (39.0) 530 (62.1) 227 (26.6) 97 (11.4)
Sex
Male 857 (39.1) 522 (60.9) 335 (39.1) 207 (61.8) 85 (25.4) 43 (12.8)
Female 1334 (60.9) 815 (61.1) 519 (38.9) 323 (62.2) 142 (27.4) 54 (10.4)
Age group
<35 205 (9.4) 157 (76.6) 48 (23.4) 38(79.2) 9(18.8) 1 (2.1)
35–44 333 (15.2) 220 (66.1) 113 (33.9) 77 (68.1) 31(27.4) 5 (4.4)
45–54 533 (24.4) 343 (64.4) 190 (35.7) 121 (63.7) 51 (26.8) 18(9.5)
55–64 539 (24.6) 319 (59.2) 220 (40.8) 133 (60.5) 60(27.3) 27(12.3)
≥ 65 578 (26.4) 297 (51.4) 281(48.6) 159 (56.6) 76(27.1) 46(16.4)
Marital status
Single 527 (24.1) 352 (66.8) 175 (33.2) 124 (70.9) 42 (24.0) 9 (5.1)
Married 1161 (53.1) 703 (60.6) 458 (39.5) 292 (63.8) 115 (25.1) 51 (11.1)
Widowed 344 (15.7) 182 (52.9) 162 (47.1) 87 (53.7) 52 (32.1) 23 (14.2)
Divorced 153 (7.0) 95 (62.1) 58 (37.9) 27 (46.6) 18 (31.0) 13 (22.4)
Separated
No. of lifetime 
sexual Partners
0–2 455 (22.6) 288(63.3) 167 (36.7) 103 (61.7) 47 (28.1) 17 (10.2)
3–4 1051 (52.2) 628(59.8) 423 (40.3) 267 (63.1) 111 (26.2) 45 (10.6)
≥ 5 508 (25.2) 306(60.2) 202 (39.8) 123 (60.9) 51 (25.3) 28 (13.9)
Education
None                          581 (26.7)                          310 (53.4)                          271 (46.6)                          153 (56.5)                          82 (30.3)                          36 (13.3)                         
1–5 years 878 (40.3) 539 (61.4) 339 (38.6) 219 (64.6) 83 (24.5) 37 (10.9)
≥ 6 years 719 (33.0) 479 (66.6) 240 (33.4) 156 (65.0) 60 (25.0) 24 (10.0)
Occupation
White-collar 270 (13.5) 181 (67.0) 89 (33.0) 52 (58.4) 25 (28.1) 12 (13.5)
Non-active 237 (11.8) 138 (58.2) 99 (41.8) 68 (68.7) 21 (21.2) 10 (10.1)
Farming 97 (4.8) 56 (57.7) 41 (42.3) 27 (65.9) 7 (17.1) 7 (17.1)
Industry 559 (27.9) 378 (67.6) 181 (32.4) 109 (60.2) 47 (26.0) 25 (13.8)
Domestic 756 (37.7) 424 (56.1) 332 (43.9) 202 (60.8) 97 (29.2) 33 (9.9)
Unspecified 88 (4.4) 56 (63.6) 32 (36.4) 17 (53.1) 10 (31.3) 5 (15.6)
Place of birth
Rural 1245 (59.0) 729 (58.6) 516 (41.5) 324 (62.8) 133 (25.8) 59 (11.4)
Urban 866 (41.0) 553 (63.9) 313 (36.1) 188 (60.1) 89 (28.4) 36 (11.5)
Place of residence
Urban 1698 (79.6) 1038 (80.0) 259 (20.0) 413 (62.6) 170 (25.8) 77 (11.7)
Rural 435 (20.4) 660 (79.0) 176 (21.1) 103 (58.5) 54 (30.7) 19 (10.8)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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Results
High antibody titers (≥1:51,200) against HHV-8 in Relation 
to Demographic and Behavioral Factors
Of the 2191 HIV-1 negative samples who did not have
Kaposi's sarcoma, 854 (39.0%) were positive for antibod-
ies against HHV-8 according to the immunofluorescent
assay. Among those seropositive for HHV-8, 530 (62.1%)
have low titers (1:200), 227 (26.6%) have medium titers
(1:51,200) and 97 (11.4%) have highest titers
(1:204,800). Table 1 provides some socio-demographic
information about our sample in relation to HHV-8 infec-
tion and level of anti-HHV-8 antibody titers.
The prevalence of high titers did not differ significantly by
sex being 38.2% (128/335) in men and 37.8% (196/518)
in women (p = 0.62). However, the prevalence of high tit-
ers increased linearly with age from 20.8% in those under
35 years (10/48), 31.9% in those 35–44 (36/113), 36.3%
for ages 45–54 (69/190), 39.6% for ages 55–64 (87/220)
to 43.4% (122/281) in those 65 years or older (p-trend
=0.001). Anti-HHV-8 high antibody titers were not associ-
ated with educational status (p = 0.30), place of birth (p =
0.10), province of birth (p = 0.36), place of residence (p =
0.18) or province of residence (p = 0.37) (Table 2).
The results for variables characterizing wealth in South
Africa are displayed in Table 3. A few of the factors associ-
ated with poverty were linked with an increased risk of
high anti-HHV-8 antibody titers. The risk of high anti-
HHV-8 antibody titers was increased in those who lived in
structures that were constructed out of tin, mud, wood or
other building materials as opposed to brick (OR = 1.49,
95%CI 1.01–2.21; p = 0.04). The risk of high anti-HHV-8
antibody titers was lower in those who had used electricity
20 years ago both for fuel to cook food and also as a
means to heat their homes (for warmth) (OR = 0.44,
Table 2: Socio-demographic factors in relation to the risk of high anti-HHV-8 titers (≥ 1:51, 200) *
Characteristic high titer/total pos (%)¥ aOR * 95%CI
Sex
Male§ 128/335 (38.2) 1.0
Female 196/518 (37.8) 1.08 (0.80–1.45)
Test of Homogeneity¶ χ2 = 0.25, p = 0.62
Age group
<35§ 10/48 (20.8) 1.0
35–44 36/113 (31.9) 1.76 (0.79–3.93)
45–54 69/190 (36.3) 2.16 (1.01–2.41)
55–64 87/220 (39.6) 2.48 (1.18–5.25)
≥ 65 122/281 (43.4) 2.96 (1.42–6.19)
Test for trend¶ χ2 = 11.16, p = 0.001
Educational level
None§ 118/270 (43.7) 1.0
1–5 120/339 (35.4) 0.75 (0.54–1.05)
≥ 6 years 84/240 (35.0) 0.83 (0.57–1.21)
Test for trend¶ χ2 = 1.08, p = 0.30
Place of birth
Rural § 192/516 (37.2) 1.0
Urban 125/312 (40.1) 1.29 (0.95–1.74)
Test of Homogeneity¶ χ2 = 2.73, p = 0.10
Place of birth
Other§ 212/558 (38.0) 1.0
Gauteng 112/290 (38.6) 1.16 (0.85–1.56)
Test of Homogeneity¶ χ2 = 0.84, p = 0.36
Place of residence
Urban§ 247/659 (37.5) 1.0
Rural 73/176 (41.5) 1.26 (0.89–1.78)
Test of Homogeneity¶ χ2 = 1.84, p = 0.18
Place of residence
Gauteng§ 243/648 (37.5) 1.0
Other 81/205 (39.5) 1.15 (0.83–1.60)
Test of Homogeneity¶ χ2 = 0.82, p = 0.37
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients 
served as the reference group. ¶ All values were calculated with the χ2 test with 1 df unless noted otherwise.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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Table 4: Factors related to smoking and alcohol use in relation to high anti-HHV-8 antibody titers* 
Characteristic High titer/total pos (%)¥ aOR * 95%CI
Smoke cigarettes/pipes
No§ 179/486 (36.8) 1.0
Past 96/233 (41.2) 1.12 (0.77–1.62)
Yes 46/128 (35.9) 1.00 (0.64–1.57)
Test of Homogeneity¶ χ2 (2df) = 0.43, p = 0.80
Use of snuff
No§ 255/691 (36.9) 1.0
Past 22/57 (38.6) 0.97 (0.54–1.71)
Current 47/101 (46.5) 1.48 (0.95–2.30)
Test of Homogeneity¶ χ2 (2df) = 2.56, p = 0.11
Consumption of maize beer
Never§ 277/761 (36.4) 1.0
Less than 1× week 18/50 (36.0) 0.92 (0.51–1.69)
More than 1× week 13/17 (76.5) 5.10 (1.64–15.87)
Most days 13/20 (65.0) 3.07 (1.19–7.90)
Test for Trend¶ χ2 = 9.49, p = 0.002
Consumption of sorghum beer
Never§ 250/692 (36.1) 1.0
Less than 1× week 47/116 (40.5) 1.12 (0.74–1.70)
More than 1× week 15/25 (60.0) 2.46 (1.08–5.64)
Most days 7/13 (53.9) 1.93 (0.64–5.86)
Test for Trend¶ χ2 = 4.29, p = 0.04
Consumption of other homemade beer
Never§ 249/636 (39.2) 1.0
Less than 1× week 43/151 (28.5) 0.52 (0.34–0.78)
More than 1× week 18/38 (47.4) 1.18 (0.60–2.31)
Most days 7/18 (38.9) 0.91 (0.34–2.41)
Test for Trend¶ χ2 = 1.46, p = 0.23
Consumption of homemade spirits
Never§ 284/776 (36.6) 1.0
Less than 1× week 15/27 (55.6) 2.26 (1.03–5.00)
More than 1× week 4/8 (50.0) 1.60 (0.39–6.53)
Most days 13/25 (52.0) 2.05 (0.91–4.60)
Test for Trend¶ χ2 = 5.11, p = 0.02
Consumption of commercial beer
Never§ 187/508 (36.8) 1.0
Less than 1× week 21/48 (43.8) 1.32 (0.72–2.43)
More than 1× week 38/81 (46.9) 1.35 (0.83–2.21)
Most days 74/211 (35.1) 0.85 (0.58–1.250
Test for Trend¶ χ2 = 0.24=, p = 0.63
Consumption of commercial spirits
Never§ 257/680 (37.8) 1.0
Less than 1× week 29/82 (35.4) 0.85 (0.52–1.39)
More than 1× week 12/39 (30.8) 0.68 (0.33–1.41)
Most days 22/45 (48.9) 1.59 (0.85–2.99)
Test for Trend¶ χ2 = 0.37, p = 0.54
Consumption of wine
Never§ 278/733 (37.9) 1.0
Less than 1× week 23/68 (33.8) 0.83 (0.49–1.41)
More than 1× week 3/6 (50.0) 1.58 (0.31–8.01)
Most days 13/27 (48.2) 1.63 (0.75–3.56)
Test for Trend¶ χ2 = 0.90, p = 0.34BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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95%CI 0.25–0.78; p = 0.005 for cooking; OR = 0.43
95%CI 0.25–0.73; p = 0.004 for warmth). Similarly, those
individuals who reported that their eyes had watered in
their homes as a result of excessive smoke exposure for
more than 5 years (potentially related to the use of coal or
wood for fuel) also had an increased risk of having high
anti-HHV-8 titers (OR = 1.56, 95%CI 1.16–2.08; p =
0.003). Other variables associated with socioeconomic
status (occupational status, cooking food indoors versus
outdoors, and employed/unemployed) were not associ-
ated with high HHV-8 titers.
Table 4 displays the results for variables characterizing
smoking and alcohol use in this population. We did not
find any association between being a current or past
smoker, the use of snuff, consumption of commercial
beers, commercial spirits, wine and increased risk for high
titers. We did find an increased risk of high titers among
those who consumed traditional maize and sorghum
beers with increased risk for those consuming maize beer
more than once a week (OR = 5.10, 95%CI 1.64–15.87)
and for those consuming most days (OR = 3.07, 95%CI
1.19–7.90; p-trend = 0.002). Among those who drink tra-
ditional sorghum beer more than once a week risk was
also elevated (OR = 2.46, 95%CI 1.08–5.64; p-trend =
0.04). Similarly, consumption of homemade spirits was
also associated with an increased risk of having high titers
with increased risk for those consuming homemade spir-
its less than one time a week (OR = 2.26, 95%CI 1.03–
5.00; p-trend = 0.02).
We analyzed consumption of alcoholic beverages dichot-
omizing study participants into non-drinkers and drink-
ers and found no association between being a drinker of
alcoholic beverages and increased risk for high titers.
However, dichotomizing participants into those who
drink maize and/or sorghum beers with those who do
not, the results were marginally significant with drinkers
at marginally increased risk (OR 1.37, 95%CI 0.95–1.97;
p = 0.09). In South Africa, sorghum beer is often supple-
mented with maize as a filler as it is cheaper; as maize will
supplement sorghum beers, we thought it was necessary
to look at the combined group of maize and sorghum to
indicate overall exposure to maize.
In Table 5, we looked at associations between markers of
sexual activity and reproductive risk factors and high anti-
HHV-8 titers. The only factor that had any statistical sig-
nificance for high anti-HHV-8 titers was marital status
with those individuals who were separated/divorced hav-
ing increased risk in comparison with unmarried individ-
uals (OR = 2.44, 95%CI 1.30–4.58; p = 0.01). We did not
find any associations with number of sexual partners (p-
trend = 0.54). We also did not find any associations
between the various reproductive risk factors including
age at menarche, parity, use of oral and injectable contra-
ceptives and risk for high HHV-8 titers.
Those risk factors from Tables 2–5 that were significantly
associated with high anti-HHV-8 antibody titers at the 1%
level are summarized in Table 6. After adjustment for age
group, sex and each other, 4 variables remained inde-
pendently associated with high anti-HHV-8 titers. People
with high anti-HHV-8 titers were more likely to be older
(p-trend = 0.04, OR for ≥ 65 years = 2.38, 95%CI 1.04–
5.44; p = 0.04), separated or divorced (OR = 2.73, 95%CI
1.41–5.28; p = 0.003), consuming traditional maize beer
more than one time a week (OR = 4.16, 95%CI 1.26–
13.80; p = 0.02; p-trend for increasing consumption =
0.05) and were less likely to have used electricity for cook-
ing 20 years ago (OR = 0.50, 95%CI 0.27–0.91; p = 0.02).
Discussion
The primary aim of this study was to identify risk factors
for high HHV-8 titers in HIV-seronegative, black South
African adults as means to identify potential co-factors in
the development of Kaposi's sarcoma. Studies have found
that the risk of KS is increased with increasing anti-HHV-
8 titers [13,14]. Similarly, high anti-HHV-8 titers have
been correlated with high HHV-8 viral load, as it is
believed that the titer of antibodies against HHV-8 reflects
viral load [16]. As has been described by Sitas et al., 1999,
Consumption of any alcohol
No§ 162/432 (37.5) 1.0
Yes 159/416 (38.2) 0.94 (0.69–1.29)
Test of Homogeneity¶ χ2= 0.13, p = 0.72
Consumption of any maize or sorghum 
traditional beers
No§ 245/682 (35.9) 1.0
Yes 75/166 (45.2) 1.37 (0.95–1.97)
Test of Homogeneity¶ χ2 = 2.85, p = 0.09
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients 
served as the reference group. ¶ All values were calculated with the χ2 test with 1 df unless noted otherwise.
Table 4: Factors related to smoking and alcohol use in relation to high anti-HHV-8 antibody titers*  (Continued)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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Table 5: Factors related to sexual exposures and reproduction in relation to high anti-HHV-8 antibody titers 
high titer/total pos (%)¥ aOR * 95%CI
Number of lifetime husbands/wives
0–1§ 247/633 (39.0) 1.0
≥ 2 20/45 (44.4) 1.26 (0.68–2.35)
Test for Trend¶ χ2 = 0.55, p = 0.46
Marital status
Single§ 51/175 (29.1) 1.0
Married 166/458 (36.2) 1.11 (0.73–1.69)
Widowed 75/162 (46.3) 1.54 (0.92–2.59)
Separated/Divorced 31/57 (54.4) 2.44 (1.30–4.58)
Test of Homogeneity¶ (3 df) χ2 = 10.6, p = 0.01
Number of lifetime sexual partners
0–2§ 64/166 (38.6) 1.0
3–4 156/423 (36.9) 0.94 (0.65–1.38)
≥ 5 79/202 (39.1) 1.11 (0.71–1.74)
Test for Trend¶ χ2 = 0.37, p = 0.54
Pregnant (in lifetime)
Yes§ 189/501 (37.7) 1.0
No 8/17 (47.1) 1.65 (0.61–4.49)
Test of Homogeneity¶ χ2 = 0.95, p = 0.33
Times pregnant (in lifetime)
1§ 11/39 (28.2) 1.0
2–3 57/149 (38.3) 1.69 (0.77–3.69)
4–5 54/142 (38.0) 1.50 (0.68–3.29)
≥ 6 68/173 (39.3) 1.45 (0.67–3.15)
Test for Trend¶ χ2 = 0.03, p = 0.87
Times miscarriage (in lifetime)
0§ 6/12 (50.0) 1.0
1 37/107 (34.6) 0.56 (0.17–1.89)
≥ 2 39/100 (39.0) 0.61 (0.18–2.06)
Test for Trend¶ χ2 = 0.10, p = 0.73
Parity
0–2§ 53/140 (37.9) 1.0
3–4 57/174 (32.8) 0.73 (0.45–1.18)
≥ 5 74/176 (42.1) 0.99 (0.62–1.59)
Test for Trend¶ χ2 = 0.00, p = 0.95
Number of children (born alive) (for men)
0–1§ 10/26 (38.5) 1.0
2–3 29/82 (35.4) 0.80 (0.31–2.06)
4–5 31/80 (38.8) 0.76 (0.29–2.01)
≥ 6 49/126 (38.9) 0.69 (0.26–1.79)
Test for Trend¶ χ2 = 0.50, p = 0.48
Number of mothers and fathers (children)
1§ 237/608 (39.0) 1.0
≥ 2 67/197 (34.0) 0.82 (0.58–1.16)
Test for Trend¶ χ2 = 1.30, p = 0.25
Age when periods began
10–13§ 17/39 (43.6) 1.0
14 34/81 (42.0) 0.93 (0.42–2.04)
15 53/166 (31.9) 0.55 (0.27–1.14)
≥ 16 91/227 (40.1) 0.77 (0.38–1.56)
Test for Trend¶ χ2 = 0.46, p = 0.50
Age when periods ended
≤ 45§ 32/94 (34.0) 1.0
46–49 40/100 (40.0) 1.11(0.60–2.08)
≥ 50 85/198 (42.9) 1.24 (0.69–2.23)
Test for Trend¶ χ2 = 0.74, p = 0.39BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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the relationship between high anti-HHV-8 titers and KS
may be similar to the relationship between EBV and Afri-
can Burkitt's lymphoma [28] and nasopharyngeal cancer
[29]. For these two cancers, high antibody titers correlate
well with the risk of disease.
In addition to HIV infection, which dramatically increases
risk for KS, which has been well described, the discrepancy
between the geographical distribution of KS both prior to
and with the AIDS epidemic suggests the presence of an
additional co-factor in the development of this malig-
nancy [7,30]. As Dedicoat and Newton note, HHV-8 is
common in Botswana (76–87% seroprevalence) and the
Gambia (29–84% seroprevalence) but KS was rare in
these areas prior to the HIV epidemic. Among the commu-
nity of approximately 45,000 Ethiopian Jews in Israel,
HHV-8 seroprevalence is between 39–57%, however,
there has been only one case of KS documented from
1982 to 1998 [8].
We examined approximately 50 potential risk factors in
relation to high anti-HHV-8 titers. In our final analysis,
only those factors that were significant at the 1% level
were considered in the multivariate model. Risk factors
that were significant for high anti-HHV-8 titers included
older age and socioeconomic variables. The associations
we found between age and increased risk for high HHV-8
titers concur with results from other studies [18,31]. In
contrast with the findings of Plaincoulaine et al. 2002,
however, we found no greater risk for high HHV-8 titers in
males than females. Looking at a subset of our sample
above age 65, we also found no greater risk for males than
females with high titers being 43.9% (68/155) in men
and 42.9% (54/126) in women (χ2 (1df) = 0.28, p = 0.59).
Other studies have found that the incidence of KS is
higher in males than females in endemic areas such as
sub-Saharan Africa and the Mediterranean region
[10,32,33]. As we found no difference between males and
female in risk for high anti-HHV-8 titers, to explain this
discrepancy, there may be additional risk factors for the
development of KS.
Increasing titers associated with increasing age may be
related to the natural aging process or may be a marker for
length of infection as suggested by other studies [17]. It is
difficult to speculate about length of infection with this
cross-sectional, prevalence data. Risk factors for high titers
potentially include sexual risk factors. Although we did
not find any associations between lifetime number of sex-
ual partners and high anti-HHV-8 antibody titers, we did
find an association between being separated/divorced and
increased risk for high anti-HHV-8 antibody titers. Being
separated or divorced could be a proxy for having more
sexual partners, particularly for women, who may find
themselves impoverished after divorce and in need of
engaging in survival sex or sex work. Alternatively, being
divorced or separated may suggest low socioeconomic
status.
High HHV-8 titers were associated with variables measur-
ing socioeconomic status. Using electricity 20 years ago
was protective. Electricity was used by a fraction of the
urban and rural black South African population 20 years
ago and was a good marker of socioeconomic status at
that time. In our study, only 11.7% (257/2191) had
access to electricity 20 years ago. This contrasts with the
almost universal access to electricity in urban areas of
Gauteng province (the province where 76.6% (1681/
2191) of the sample lives) as reported in the 1996 census
[34]. Having been born in an urban area was marginally
associated with increased risk (p = 0.08) as was using
cheaper, non-brick building materials such as tin, mud or
wood for home construction (p = 0.09). Crowding may be
more of a problem in urban areas and in poorer house-
holds and could be a risk factor for high titers. Research
has indicated that stressors can increase EBV antibody tit-
ers through the steady-state expression of latent herpes
viruses [35,36]; it is possible that stressors correlated with
low SES may account for an increase in anti-HHV8 titers.
However, high anti-HHV-8 antibody titers may also be a
marker of length of infection [17] particularly as those
who were living in a higher SES environment 20 years ago
are protected against having high HHV-8 titers. As this
Oral contraceptives
No§ 168/424 (39.6) 1.0
Yes 25/86 (29.1) 0.69 (0.40–1.17)
Test of Homogeneity¶ χ2 = 1.88, p = 0.17
Injectable contraceptives
No§ 165/425 (38.8) 1.0
Yes 28/87 (32.2) 0.93 (0.55–1.59)
Test of Homogeneity¶ χ2 = 0.07, p = 0.80
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 sex. ¥ Data were not available for all patients for all variables. § These patients 
served as the reference group. ¶ All values were calculated with the χ2 test with 1 df unless noted otherwise.
Table 5: Factors related to sexual exposures and reproduction in relation to high anti-HHV-8 antibody titers  (Continued)BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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study is based on prevalent HHV-8 infection, we can only
hypothesize about the timing and length of infection in
relation to risk for high anti-HHV-8 antibody titers.
Interestingly, an association with the consumption of
maize beer was a significant risk factor for high titers.
Given the association between consumption of tradition-
ally brewed alcoholic beverages and high serum ferritin
iron concentrations in black South Africans [37,38], con-
sumption of traditional beers may facilitate the develop-
ment of Kaposi's sarcoma. It has been reported that
traditional beers have high concentrations of ionized, bio-
available iron (between 82.0 mg/l) as a result of being
brewed and fermented in iron-clad pots [39,40]. Ziegler et
al. has reported that there may be an association between
exposure to the iron-rich soils of East and Central Africa
Table 6: Risk factors for high anti-HHV-8 antibody titers
OR (high titers)‡ (95%CI) p-value
Age group
<35§ 1.0
35–44 1.64 (0.71–3.77) 0.25
45–54 1.79(0.80–3.98) 0.16
55–64 2.03 (091–4.57) 0.09
≥ 65 2.38 (1.04–5.44) 0.04
Test for trend† χ2 = 4.45, p = 0.04
Place of birth
Rural§ 1.0
Urban 1.33 (0.97–1.84) 0.08
Test of Homogeneity† χ2 = 3.10, p = 0.08
Material in Walls
of Housing
Brick§ 1.0
Other 1.43 (0.94–2.17) 0.09
Test of Homogeneity† χ2 = 2.86, p = 0.09
Type of fuel used for cooking
20 years Ago
Other§ 1.0
Electricity 0.50 (0.27–0.91) 0.02
Test of Homogeneity† χ2 = 5.19, p = 0.02
Eyes water in house (from smoke)
No§ 1.0
Yes/(More than 5 Years) 1.27 (0.92–1.75) 0.14
Test of Homogeneity† χ2 = 2.16, p = 0.14
Marital status
Single§ 1.0
Married 1.20 (0.77–1.85) 0.42
Widowed 1.52 (0.89–2.59) 0.13
Separated/Divorced 2.73 (1.41–5.28) 0.003
Test of Homogeneity† (3df) χ2 = 10.31, p = 0.02
Consumption of maize beer
Never§ 1.0
Less than 1× week 0.74 (0.38–1.42) 0.36
More than 1× week 4.16 (1.26–13.80) 0.02
Most Days 2.18 (0.79–6.04) 0.13
Test for Trend† χ2 = 3.72, p = 0.05
Consumption of homemade spirits
Never§ 1.0
Less than 1× week 2.16 (0.93–5.03) 0.07
More than 1× week 1.00 (.20–5.05) 0.99
Most Days 1.68 (0.72–3.92) 0.23
Test for Trend† χ2 = 2.25, p = 0.13
† All values were calculated with the χ2 test with 1df unless noted otherwise. ‡ In the multivariate model, all bivariately statistically significant 
variables at p = 0.1 are included and odds ratios are also adjusted for sex. Each variable was adjusted for all other variables in the table. The 
Hosmer-Lemeshow goodness-of-fit statistic = 5.66 with 8 df (p = 0.69). § These patients served as the reference groupBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/21
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and the development of KS [12]. In a case-control study of
KS in HIV positive Ugandan patients, Ziegler et al. found
that those who drank home-made beer less than once a
week had an OR of 2.65 95%CI (1.9–3.8) although there
was no trend in risk with increased consumption [11].
Our association with maize beer, however, could be a
chance finding since approximately 50 significance tests
were performed. Unlike the protective association found
between smoking and decreased KS risk by Goedert et al.
[41], we found no association between smoking and high
anti-HHV-8 antibody titers.
As this case control study was based on prevalent HHV-8
infection, it is important to emphasize the limitations of
using this type of data. We were unable to establish a tem-
poral relationship between high anti-HHV-8 antibody tit-
ers and the multitude of predictors evaluated in this study.
Additionally, as some of our conclusions differ from stud-
ies that have evaluated risk factors for KS, there may be
different risk factors for KS and anti-HHV-8 antibody tit-
ers that should be evaluated in future studies.
Conclusion
The associations we found between age, socioeconomic
status and consumption of traditionally brewed alcoholic
beverages and high anti-HHV-8 titers need to be exam-
ined in a prospective study. If there is an association
between the development of KS and consumption of tra-
ditionally brewed beers due to the high levels of bio-avail-
able iron in these beers, public health campaigns could be
directed at the replacement of iron containers with earth-
enware pots [42]. Additionally, specifics of the low socio-
economic environment that may increase risk for high
anti-HHV-8 antibody titers such as crowding need to be
examined in prospective study.
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